UA95583C2 - Composition for treatment of displastic processes of uterine cervix - Google Patents

Composition for treatment of displastic processes of uterine cervix

Info

Publication number
UA95583C2
UA95583C2 UAA201011132A UAA201011132A UA95583C2 UA 95583 C2 UA95583 C2 UA 95583C2 UA A201011132 A UAA201011132 A UA A201011132A UA A201011132 A UAA201011132 A UA A201011132A UA 95583 C2 UA95583 C2 UA 95583C2
Authority
UA
Ukraine
Prior art keywords
uterine cervix
displastic
processes
treatment
composition
Prior art date
Application number
UAA201011132A
Other languages
Russian (ru)
Ukrainian (uk)
Inventor
Всеволод Иванович Киселев
Original Assignee
Общество С Ограниченной Ответственностью "Нанофарма
"Киселев Всеволод Иванович
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Общество С Ограниченной Ответственностью "Нанофарма, "Киселев Всеволод Иванович filed Critical Общество С Ограниченной Ответственностью "Нанофарма
Publication of UA95583C2 publication Critical patent/UA95583C2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

The invention relates to medicine and the pharmaceutical industry, in particular to new agents for treating dysplastic changes in the uterine cervix and the rectal mucosa. The inventive medicinal agent for treating dysplastic changes in the uterine cervix and the rectal mucosa is in the form of a suppository and is characterized in that it contains 3,3'-diindolylmethane, epigallocatechin-3-gallate, a catalyst of the inhibitory activity of epigallocatechin-3-gallate with respect to DNA methyltransferase, consisting of Mgcations in the form of a pharmaceutically acceptable magnesium salt, a lipophilic base containing solid fat, polyvinylpyrrolidone and butylhydroxyanisole and/or butylhydroxytoluene. The agent is effective against severe dysplastic diseases.
UAA201011132A 2008-09-04 2009-08-18 Composition for treatment of displastic processes of uterine cervix UA95583C2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
RU2008135764/15A RU2395281C2 (en) 2008-09-04 2008-09-04 Pharmaceutical composition for treatment of dysplastic processes of cervix

Publications (1)

Publication Number Publication Date
UA95583C2 true UA95583C2 (en) 2011-08-10

Family

ID=41797309

Family Applications (1)

Application Number Title Priority Date Filing Date
UAA201011132A UA95583C2 (en) 2008-09-04 2009-08-18 Composition for treatment of displastic processes of uterine cervix

Country Status (4)

Country Link
EA (1) EA018383B1 (en)
RU (1) RU2395281C2 (en)
UA (1) UA95583C2 (en)
WO (1) WO2010027294A1 (en)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2454232C2 (en) * 2010-09-16 2012-06-27 Федеральное государственное бюджетное учреждение "Российский онкологический научный центр имени Н.Н. Блохина" Российской академии медицинских наук (ФГБУ "РОНЦ им. Н.Н. Блохина" РАМН) Application of triindolyl methane derivatives as anticancer drugs
RU2456987C1 (en) * 2011-03-21 2012-07-27 Сергей Владимирович Енгашев Method for producing gelatine capsules of 3,31-diindolylmethane
GB2533381A (en) * 2014-12-18 2016-06-22 Nordic Labs Ltd Novel treatment of STIs
RU2601621C2 (en) * 2015-03-18 2016-11-10 Общество с ограниченной ответственностью "Фармацевтический завод иммунных лекарственных средств" Sodium deoxyribonucleate suppositories, rectal and vaginal
GB2542106A (en) * 2015-04-01 2017-03-15 Nordic Labs Ltd Novel treatment of STIs
RU2601893C1 (en) * 2015-11-30 2016-11-10 Всеволод Иванович Киселев Drug preparation based on indole-3-carbinol with increased epigenetic activity
US20200179337A1 (en) * 2016-05-16 2020-06-11 Aktsionernoe Obschestvo "Veles Farma" Means for treating sexually transmitted infections
CN108969602A (en) * 2018-09-29 2018-12-11 南京依美生物科技有限公司 It is a kind of to treat the Chinese medicine composition and preparation method that human papilloma virus sun is turned out cloudy

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1275905B1 (en) * 1995-03-14 1997-10-24 Indena Spa POLYPHENOLIC FRACTIONS OF TEA, THEIR USE AND FORMULATIONS THAT CONTAIN THEM
RU2196568C1 (en) * 2001-08-08 2003-01-20 Киселев Всеволод Иванович Pharmaceutical composition for prophylaxis and treatment of uterus cervix dysplasia and cancer and larynx papillomatosis and method of prophylaxis and treatment of said sicknesses based on thereof
CA2471932A1 (en) * 2002-01-11 2003-07-17 Matthias Rath A nutrient pharmaceutical formulation comprising polyphenols and use in treatment of cancer
RU2318510C1 (en) * 2006-04-19 2008-03-10 Всеволод Иванович Киселев 3,3'-diindolylmethane (metindol)-base vaginal suppository
RU2315594C1 (en) * 2006-09-01 2008-01-27 Всеволод Иванович Киселев Anti-estrogenic and anti-proliferative agent for treatment and prophylaxis of female reproductive system diseases

Also Published As

Publication number Publication date
RU2395281C2 (en) 2010-07-27
WO2010027294A1 (en) 2010-03-11
EA201100417A1 (en) 2011-10-31
EA018383B1 (en) 2013-07-30
RU2008135764A (en) 2010-03-10

Similar Documents

Publication Publication Date Title
UA95583C2 (en) Composition for treatment of displastic processes of uterine cervix
SG150531A1 (en) Use of meloxicam for the treatment of respiratory diseases in pigs
MX2011013902A (en) Treatment of multiple sclerosis with laquinimod.
MX2009002196A (en) Buprenophine-wafer for drug substitution therapy.
AR060019A1 (en) PHARMACEUTICAL COMPOSITION, PRODUCT AND TREATMENT METHOD FOR A COGNITIVE DISORDER AND USES OF AN ACETILCOLINESTERASE INHIBITOR AND A 5- HT6 ANTAGONIST IN THE MANUFACTURE OF A MEDICINAL PRODUCT FOR THE TREATMENT OF A COGNITIVE DISORDER
MX2009003372A (en) Non-mucoadhesive film dosage forms.
HUP0401867A2 (en) Use of derivatives of valproic acid amides and 2-valproenic acid amides for the treatment or prevention of pain and/or headache disorders
JP2015532296A5 (en)
IL203747A (en) Use of sex steroid precursor in the manufacture of a medicament for delivering 13 mg or less daily dosage intrvaginally for the treatment of vaginal diseases and a vaginal pharmaceutical composition comprising same
UA90858C2 (en) Controlled-release formulations containing vardenafil
AR070047A1 (en) THERAPEUTIC TREATMENTS AGAINST CANCER. COMPOSITION THAT INCLUDES A HEDGEHOG INHIBITOR.
UA90893C2 (en) Oral dosage forms of gemcitabine derivatives
RU2004103074A (en) USE OF CYCLOPAMINE IN TREATMENT OF PSORIASIS
WO2007062093A3 (en) Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
UA81573C2 (en) Use of agomelatine for the preparation of medicaments for the treatment of sleep disorders in depressed patients
MX2021002321A (en) Novel methods.
BRPI0518448A2 (en) pharmaceutical compositions comprising a camptothecin derivative
MX2010009624A (en) 1-benzyl-3-hydr0xymethylindaz0le derivatives and use thereof in the treatment of diseases based on the expression of mcp-1, and cx3cr1.
MX2011011058A (en) Selective ep4 receptor agonistic substance for treatment of cancer.
JP2014526559A5 (en)
MX2008002456A (en) Use of ambroxol for the treatment of rhinovirus infections.
PH12020551911A1 (en) Use of riluzole oral disintigrating tablets for treating diseases
MX2021008536A (en) Modified release tablet formulations containing phosphodiesterase inhibitors.
AR045865A1 (en) THE USE OF A POLYPHENOL FOR THE TREATMENT OF A CANCEROSE OR PRE-CANCERAL SKIN INJURY
FI3345604T3 (en) Nalmefene for reduction of alcohol consumption in specific target populations